An observational study in Myotonic Dystrophy 1, sponsored by Huashan Hospital. Enrolling by invitation at 22 sites in China. Per ClinicalTrials.gov, last updated 2026-06-02.
Sponsored by Huashan Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Myotonic dystrophy type 1 (DM1) is an autosomal dominant multisystem disorder caused by an expanded CTG trinucleotide repeat in the 3' untranslated region of the DMPK gene. Beyond myotonia and progressive skeletal muscle weakness, DM1 involves the cardiac, respiratory, central nervous, gastrointestinal, endocrine, and ocular systems, and respiratory and cardiac involvement are the leading causes of disability and death. Systematic, long-term outcome data in Chinese DM1 patients are lacking.
C-DMCOS-DM1 is a multicenter, prospective, observational cohort study that systematically records demographic data, multisystem involvement, and predefined disability-related clinical outcome events in genetically confirmed Chinese DM1 patients, with regular follow-up every 3 to 6 months. The study also collects residual blood, skeletal muscle, myocardium (when a pacemaker is implanted), and urine specimens for transcriptomic and other molecular studies. The aims are to characterize the disease burden of Chinese DM1 patients, identify risk and prognostic factors for disabling outcomes, and build risk-prediction models to inform follow-up, management, and future clinical trials.
This multicenter, prospective, observational cohort study (no randomization, no control, no intervention) enrolls genetically confirmed DM1 patients across Chinese neuromuscular centers and follows them every 3 to 6 months. At baseline and each visit, the study collects demographics, clinical subtype, symptoms and rating scales, manual muscle testing and the Muscular Impairment Rating Scale (MIRS), quantitative motor measures (grip strength, 10-Metre Walk Test [10MWT], Video Hand Opening Time [vHOT]), cardiac assessment (electrocardiography and 24-hour Holter), pulmonary function testing, echocardiography, laboratory tests, computerized cognitive assessment, and video and voice recordings of gait, hand grip, and facial movement for artificial-intelligence analysis. Wearable devices are encouraged for continuous monitoring of heart rate and heart rate variability, blood oxygen saturation, respiratory rate, sleep and nocturnal respiratory events, and daily physical activity.
Predefined disability-related outcome events are tracked cumulatively, including loss of independent ambulation, respiratory failure, non-invasive or invasive mechanical ventilation, tracheostomy, cardiac pacemaker or implantable cardioverter-defibrillator (ICD) implantation, early cataract surgery, malignancy, and death. Residual blood, skeletal muscle, myocardium (when a pacemaker is implanted), and urine specimens are collected for RNA sequencing, mitochondrial DNA analysis, and other molecular studies. Statistical analysis includes descriptive characterization, Kaplan-Meier and Cox proportional-hazards survival analysis, competing-risk models, and multivariable regression to identify risk and prognostic factors and to build risk-prediction models.
127 studies on the registry are indexed under Myotonic Dystrophy; 50 are open to participants now.
This study's planned enrollment of 1,000 is above the median of 100 across 56 observational studies indexed under Myotonic Dystrophy.
Browse Myotonic Dystrophy studies →Huashan Hospital is the lead sponsor of 248 studies on the registry; 105 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The patients will be diagnosed and invited to join this trial in each participating neuromuscular diagnostic centers.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patient cohort
Diagnostic Test: MRI scan · Diagnostic Test: Electrocardiography · Diagnostic Test: Pulmonary function test · Diagnostic Test: Electrocardiography and 24-hour Holter monitoring · Procedure: Skeletal muscle biopsy (residual specimen) · Device: Wearable-device continuous physiological monitoring · Behavioral: Video and voice recording for AI analysis
Brain MRI scan to evaluate the integrity of the nervous system; lower limb muscle MRI scan to evaluate fat infiltration in skeletal muscles of the lower limb
Standard 12-lead electrocardiography or Holter monitoring performed to assess cardiac conduction abnormalities and arrhythmias in patients with DM1.
Comprehensive pulmonary function testing including spirometry to assess respiratory muscle weakness and restrictive lung disease in DM1 patients.
Electrocardiography and 24-hour Holter monitoring
Skeletal muscle biopsy (residual specimen)
Wearable-device continuous physiological monitoring (heart rate, blood oxygen saturation, respiration, physical activity, sleep)
Video and voice recording for AI analysis (gait, hand grip, facial movement, speech)
Cumulative incidence and time to first major disability-related clinical outcome event
Proportion of participants experiencing, and time to first occurrence of, predefined disability-related outcome events: loss of independent ambulation, respiratory failure, non-invasive mechanical ventilation, invasive mechanical ventilation, tracheostomy, cardiac pacemaker implantation, implantable cardioverter-defibrillator (ICD) implantation, early cataract surgery, malignancy, and death. Each event is recorded with its date of first occurrence.
Time frame: From enrollment up to 10 years
Change in 10-Metre Walk Test (10MWT)
Time in seconds to walk 10 metres, assessing functional mobility.
Time frame: Baseline, Year 1, Year 3, Year 5, Year 10
Change in Video Hand Opening Time (vHOT)
Time to fully open the hand after making a fist, an objective measure of myotonia severity.
Time frame: Baseline, Year 1, Year 3, Year 5, Year 10
Change in Muscular Impairment Rating Scale (MIRS)
Five-point clinical rating of muscle impairment in DM1.
Time frame: Baseline, Year 1, Year 3, Year 5, Year 10
Change in forced vital capacity (FVC, % predicted)
Pulmonary function measure reflecting respiratory involvement.
Time frame: Baseline, Year 1, Year 3, Year 5, Year 10
Change in Epworth Sleepiness Scale (ESS)
0 to 24 scale of daytime sleepiness; higher scores indicate greater sleepiness.
Time frame: Baseline, Year 1, Year 3, Year 5, Year 10
Change in Fatigue Severity Scale (FSS)
9-item fatigue scale; higher scores indicate more severe fatigue.
Time frame: Baseline, Year 1, Year 3, Year 5, Year 10
Plan to share: No — Individual participant data will not be shared publicly. The data are subject to China's Regulations on the Administration of Human Genetic Resources. All participant data are managed anonymously and identified by study number rather than name, and are accessible only to authorized study personnel.
Started Aug 2021 (actual). Primary completion is estimated for Aug 2030, 108 months after the start.
Of 36 observational studies under Myotonic Dystrophy, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 35. This study's planned 108 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.